Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 161   

Articles published

MRK 60.28 +0.08 (0.13%)
price chart
Merck Collaborates With Pfizer Again For Its PD-1 Immunotherapy
Pfizer Inc. (PFE) and Merck & Co., Inc. (MRK) announced yesterday that they have partnered to conduct trials investigating the combined efficacy of the former's lung-cancer drug, Xalkori, along with the latter's experimental drug, Pembrolizumab ...
Advaxis, Merck to test immune therapies against prostate cancer  Reuters
Advaxis and Merck Form Collaboration to Evaluate Investigational Combination ...  Wall Street Journal
Related articles »  
Merck's Melanoma Drug To Get FDA Approval Earlier Than Expected
Merck & Co., Inc. (MRK) might obtain the US Food and Drug Administration's approval for its high-profile experimental melanoma drug earlier than expected.
Company Update: Merck & Co Inc (NYSE:MRK) � [video] Merck & Pfizer team up
Summary (NYSE:MRK) : Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide.
Merck & Co. EVP Unloads $1313400 in Stock (MRK)  WKRB News
Related articles »  
Merck & Co. Inc. (MRK) Among Biggest DJIA Losers on August 18
Shares of Merck & Co. Inc. led all laggers on the Dow Monday with a decline of 0.32%. The DJIA closed at 16,838.70, which is a 1.06% change from the previous day's close.
Related articles »  
Merck & Co. Inc. (MRK) Tops DJIA Gainers for August 22
The Dow closed at 17,001.20 on Friday, which is a -0.22% move from yesterday's close. Merck & Co. Inc. led all gainers with a 0.54% jump.
Wednesday's Analyst Moves: Pfizer Inc., Merck & Co., Inc., Bristol-Myers ...
Deutsche Bank has initiated coverage on Eli Lilly and Co (LLY ) with a �Buy� rating and a $71 price target. This price target suggests an 11% increase from the stock's current price.
Related articles »  
Merck & Co. Inc. (MRK) Among Biggest DJIA Losers on August 21
Shares of Merck & Co. Inc. led all laggers on the Dow Thursday with a decline of 1.06%. The DJIA closed at 17,039.60, which is a 0.36% change from the previous day's close.
Why Wall Street Is Not Bearish On Merck
None of the analysts covering Merck & Co., Inc. (MRK) are bearish due to the company's strong drug pipeline. However, many are not completely sure of Merck's future and have a neutral stance on the pharmaceutical.
Merck & Co., Inc. (MRK): The Grand Daddy of Pharma
Right now, Merck & Co., Inc.(NYSE:MRK), this nation's second biggest pharmaceutical maker, is a curious animal: a value stock that's priced like a growth stock.
3 Reasons Merck & Co., Inc.'s Stock Could Rise
You need to be willing to dig deeper and discover what the true growth drivers are for the company, which is exactly what we're going to do today.
Related articles »